Sergio Maluta1, Stefano Dall'Oglio1, Donald A Goer2, Nadia Marciai3. 1. Dept. of Radiotherapy, University Hospital, Verona, Italy. 2. Intraop Medical Corporation, Sunnyvale, CA, USA. 3. Dept. of Radiotherapy, Azienda Ospedaliera, Verona, Italy.
Abstract
BACKGROUND: Intraoperative radiotherapy during breast-conserving surgery is being studied as an alternative to 6 weeks of external beam radiotherapy (EBRT) for low-risk women; it can be delivered using electrons (intraoperative electron radiotherapy, IOERT) or 50-kV X-rays. MATERIALS AND METHODS: We analyzed both single institutional and randomized studies involving single-fraction IOERT treatments. Rates for ipsilateral breast tumor recurrences, disease-specific survival, and overall survival were obtained. RESULTS: IOERT had true 5-year recurrence rates of > 1.5% for ASTRO (American Society for Radiation Oncology) and ESTRO (European Society for Therapeutic Radiology and Oncology) suitable women, or for low-risk women as defined by the ELIOT trial. Women with ductal carcinoma in situ eligible for breast-conserving therapy, older women that currently receive no EBRT, and younger women with favorable biology are additional potential candidates. CONCLUSION: ASTRO suitable and ESTRO good women for accelerated partial breast irradiation are low-risk groups. Higher-risk women with favorable biology might also be suitable candidates for IOERT, providing the tumor biology can be determined prior to surgery. For intraoperative radiotherapy using 50-kV X-rays, follow-up was too short to assess the effectiveness of the treatment.
BACKGROUND: Intraoperative radiotherapy during breast-conserving surgery is being studied as an alternative to 6 weeks of external beam radiotherapy (EBRT) for low-risk women; it can be delivered using electrons (intraoperative electron radiotherapy, IOERT) or 50-kV X-rays. MATERIALS AND METHODS: We analyzed both single institutional and randomized studies involving single-fraction IOERT treatments. Rates for ipsilateral breast tumor recurrences, disease-specific survival, and overall survival were obtained. RESULTS: IOERT had true 5-year recurrence rates of > 1.5% for ASTRO (American Society for Radiation Oncology) and ESTRO (European Society for Therapeutic Radiology and Oncology) suitable women, or for low-risk women as defined by the ELIOT trial. Women with ductal carcinoma in situ eligible for breast-conserving therapy, older women that currently receive no EBRT, and younger women with favorable biology are additional potential candidates. CONCLUSION: ASTRO suitable and ESTRO good women for accelerated partial breast irradiation are low-risk groups. Higher-risk women with favorable biology might also be suitable candidates for IOERT, providing the tumor biology can be determined prior to surgery. For intraoperative radiotherapy using 50-kV X-rays, follow-up was too short to assess the effectiveness of the treatment.
Entities:
Keywords:
Academic Review; Breast cancer; Radiotherapy
Authors: Randall J Kimple; Nancy Klauber-DeMore; Cherie M Kuzmiak; Dag Pavic; Jun Lian; Chad A Livasy; WingKeung M Chiu; Dominic T Moore; Carolyn I Sartor; David W Ollila Journal: Ann Surg Oncol Date: 2011-04 Impact factor: 5.344
Authors: Stefan O Emdin; Bengt Granstrand; Anita Ringberg; Kerstin Sandelin; Lars-Gunnar Arnesson; Hans Nordgren; Harald Anderson; Hans Garmo; Lars Holmberg; Arne Wallgren Journal: Acta Oncol Date: 2006 Impact factor: 4.089
Authors: B Fisher; J Costantino; C Redmond; E Fisher; R Margolese; N Dimitrov; N Wolmark; D L Wickerham; M Deutsch; L Ore Journal: N Engl J Med Date: 1993-06-03 Impact factor: 91.245
Authors: Joan Houghton; W D George; Jack Cuzick; Catherine Duggan; Ian S Fentiman; Margaret Spittle Journal: Lancet Date: 2003-07-12 Impact factor: 79.321
Authors: R W Blamey; T Bates; U Chetty; S W Duffy; I O Ellis; D George; E Mallon; M J Mitchell; I Monypenny; D A L Morgan; R D Macmillan; J Patnick; S E Pinder Journal: Eur J Cancer Date: 2013-03-21 Impact factor: 9.162
Authors: Jayant S Vaidya; Frederik Wenz; Max Bulsara; Jeffrey S Tobias; David J Joseph; Mohammed Keshtgar; Henrik L Flyger; Samuele Massarut; Michael Alvarado; Christobel Saunders; Wolfgang Eiermann; Marinos Metaxas; Elena Sperk; Marc Sütterlin; Douglas Brown; Laura Esserman; Mario Roncadin; Alastair Thompson; John A Dewar; Helle M R Holtveg; Steffi Pigorsch; Mary Falzon; Eleanor Harris; April Matthews; Chris Brew-Graves; Ingrid Potyka; Tammy Corica; Norman R Williams; Michael Baum Journal: Lancet Date: 2013-11-11 Impact factor: 79.321
Authors: Carsten Herskind; Lin Ma; Qi Liu; Bo Zhang; Frank Schneider; Marlon R Veldwijk; Frederik Wenz Journal: Radiat Oncol Date: 2017-01-19 Impact factor: 3.481
Authors: Melvin J Silverstein; Gerd Fastner; Sergio Maluta; Roland Reitsamer; Donald A Goer; Frank Vicini; David Wazer Journal: Ann Surg Oncol Date: 2014-08-27 Impact factor: 5.344